Melissa Crouse lives in Cape Coral, Florida, surrounded by her 3 children and 9 grandchildren, who are her pride and joy. She spent her career as a middle school orchestra and choir director, but since she retired, she has [...]
Wells W. is a longtime friend of GO2 for Lung Cancer. At 91 years old, he is part of the Leadership Circle, a group of our most generous supporters. I was diagnosed with lung cancer in 1998 [...]
GO2 for Lung Cancer Chief Healthcare Delivery Officer Joelle Fathi, DNP, RN, ARNP, CTTS, FAANP, FAAN has a family history of lung cancer; both her mother and maternal grandmother were diagnosed with the disease. So, it came as no [...]
By Renee Botello MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer and Roy Herbst, MD, PhD Each year, the American Society of Clinical Oncology (ASCO) holds an annual meeting that shares novel breakthroughs and transformative research in oncology. [...]
On March 1, 2024, the U.S. Food and Drug Administration (FDA) approved the drug Rybrevant (amivantamab-vmjw) to be given in combination with carboplatin and pemetrexed in the first lining setting for people with metastatic non-small cell lung cancer (NSCLC) with [...]
Ellen S. is a three-year survivor of stage 4 (IV) non-small cell lung cancer. She retired two years ago after a 22-year career as an occupational therapist in New York. She loves to travel and hike and has visited [...]
On Nov. 16, 2023, the U.S. Food and Drug Administration (FDA) approved Augtyro (repotrectinib) for people living with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a ROS1 gene mutation. The approval was based on results from [...]
Question: My tumor’s original biopsy showed that I had non-small cell lung cancer with an EGFR biomarker. Recently, the cancer started progressing and my most recent biopsy shows that I have transformed small cell lung cancer. What does this [...]
On December 12th, 2022, the Food and Drug Administration (FDA) approved Krazati (adagrasib) for treatment of non-small cell lung cancer (nsclc) where there is a KRAS G12C mutation. This approval is for patients who have received at least one line [...]
On November 10th, 2022, the Food and Drug Administration (FDA) approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy for treatment of non-small cell lung cancer where there are no changes in ALK or EGFR. The FDA [...]